Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Frank Baiden

Showing results (71-80 of 84) with videos related to

Pageof 9
Sort By:
Tropical Medicine & International Health : TM & IH|April 3, 2025
Regulator experiences of trials during Ebola epidemics in Sierra Leone, Guinea, and the Democratic Republic of the CongoKambale Kasonia, Frank Baiden, Frédéric Le Marcis, et al.
Applied Neuropsychology. Child|July 28, 2016
Can we measure cognitive constructs consistently within and across cultures? Evidence from a test battery in Bangladesh, Ghana, and TanzaniaPenny Holding, Adote Anum, Fons J R van de Vijver, et al.
Bulletin of the World Health Organization|September 5, 2007
Setting international standards for verbal autopsyFrank Baiden, Ayaga Bawah, Sidu Biai, et al.
Global Health Action|April 4, 2022
Estimating causes of death where there is no medical certification: evolution and state of the art of verbal autopsyDaniel Chandramohan, Edward Fottrell, Jordana Leitao, et al.
Emerging Infectious Diseases|February 24, 2022
Ebola Virus Glycoprotein IgG Seroprevalence in Community Previously Affected by Ebola, Sierra LeoneDaniela Manno, Philip Ayieko, David Ishola, et al.
BMJ Open|March 10, 2017
Improving prescribing practices with rapid diagnostic tests (RDTs): synthesis of 10 studies to explore reasons for variation in malaria RDT uptake and adherenceHelen E D Burchett, Baptiste Leurent, Frank Baiden, et al.
Vaccines|August 26, 2023
The Effect of Previous Exposure to Malaria Infection and Clinical Malaria Episodes on the Immune Response to the Two-Dose Ad26.ZEBOV, MVA-BN-Filo Ebola Vaccine RegimenDaniela Manno, Catriona Patterson, Abdoulie Drammeh, et al.
The Lancet. Infectious Diseases|September 16, 2021
Safety and immunogenicity of the two-dose heterologous Ad26.ZEBOV and MVA-BN-Filo Ebola vaccine regimen in children in Sierra Leone: a randomised, double-blind, controlled trialMuhammed O Afolabi, David Ishola, Daniela Manno, et al.
The Lancet. Infectious Diseases|September 16, 2021
Safety and long-term immunogenicity of the two-dose heterologous Ad26.ZEBOV and MVA-BN-Filo Ebola vaccine regimen in adults in Sierra Leone: a combined open-label, non-randomised stage 1, and a randomised, double-blind, controlled stage 2 trialDavid Ishola, Daniela Manno, Muhammed O Afolabi, et al.
The Lancet. Infectious Diseases|October 23, 2022
Safety and immunogenicity of an Ad26.ZEBOV booster dose in children previously vaccinated with the two-dose heterologous Ad26.ZEBOV and MVA-BN-Filo Ebola vaccine regimen: an open-label, non-randomised, phase 2 trialDaniela Manno, Agnes Bangura, Frank Baiden, et al.
Pageof 9

Showing results (71-80 of 84) with videos related to

Sort By:
Pageof 9
Tropical Medicine & International Health : TM & IH|April 3, 2025
Regulator experiences of trials during Ebola epidemics in Sierra Leone, Guinea, and the Democratic Republic of the CongoKambale Kasonia, Frank Baiden, Frédéric Le Marcis, et al.
Applied Neuropsychology. Child|July 28, 2016
Can we measure cognitive constructs consistently within and across cultures? Evidence from a test battery in Bangladesh, Ghana, and TanzaniaPenny Holding, Adote Anum, Fons J R van de Vijver, et al.
Bulletin of the World Health Organization|September 5, 2007
Setting international standards for verbal autopsyFrank Baiden, Ayaga Bawah, Sidu Biai, et al.
Global Health Action|April 4, 2022
Estimating causes of death where there is no medical certification: evolution and state of the art of verbal autopsyDaniel Chandramohan, Edward Fottrell, Jordana Leitao, et al.
Emerging Infectious Diseases|February 24, 2022
Ebola Virus Glycoprotein IgG Seroprevalence in Community Previously Affected by Ebola, Sierra LeoneDaniela Manno, Philip Ayieko, David Ishola, et al.
BMJ Open|March 10, 2017
Improving prescribing practices with rapid diagnostic tests (RDTs): synthesis of 10 studies to explore reasons for variation in malaria RDT uptake and adherenceHelen E D Burchett, Baptiste Leurent, Frank Baiden, et al.
Vaccines|August 26, 2023
The Effect of Previous Exposure to Malaria Infection and Clinical Malaria Episodes on the Immune Response to the Two-Dose Ad26.ZEBOV, MVA-BN-Filo Ebola Vaccine RegimenDaniela Manno, Catriona Patterson, Abdoulie Drammeh, et al.
The Lancet. Infectious Diseases|September 16, 2021
Safety and immunogenicity of the two-dose heterologous Ad26.ZEBOV and MVA-BN-Filo Ebola vaccine regimen in children in Sierra Leone: a randomised, double-blind, controlled trialMuhammed O Afolabi, David Ishola, Daniela Manno, et al.
The Lancet. Infectious Diseases|September 16, 2021
Safety and long-term immunogenicity of the two-dose heterologous Ad26.ZEBOV and MVA-BN-Filo Ebola vaccine regimen in adults in Sierra Leone: a combined open-label, non-randomised stage 1, and a randomised, double-blind, controlled stage 2 trialDavid Ishola, Daniela Manno, Muhammed O Afolabi, et al.
The Lancet. Infectious Diseases|October 23, 2022
Safety and immunogenicity of an Ad26.ZEBOV booster dose in children previously vaccinated with the two-dose heterologous Ad26.ZEBOV and MVA-BN-Filo Ebola vaccine regimen: an open-label, non-randomised, phase 2 trialDaniela Manno, Agnes Bangura, Frank Baiden, et al.
Pageof 9